Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tebipenem Pivoxil Hydrobromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 6,032Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Spero Announces First Patient, First Visit for Ph 3 Trial Evaluating Tebipenem
    Spero Announces First Patient, First Visit for Ph 3 Trial Evaluating Tebipenem

    02 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/02/2802657/0/en/Spero-Therapeutics-Announces-First-Patient-First-Visit-for-Phase-3-PIVOT-PO-Trial-Evaluating-Tebipenem-HBr-in-Complicated-Urinary-Tract-Infections.html

    GLOBENEWSWIRE
    02 Jan 2024
    Share Share
    Spero Therapeutics Announces Agreement with FDA for Phase 3 of Tebipenem HBr
    Spero Therapeutics Announces Agreement with FDA for Phase 3 of Tebipenem HBr

    31 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/31/2714858/0/en/Spero-Therapeutics-Announces-Special-Protocol-Assessment-Agreement-with-FDA-for-Phase-3-PIVOT-PO-Trial-of-Tebipenem-HBr.html

    GLOBENEWSWIRE
    31 Jul 2023
    Share Share
    Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published
    Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published

    06 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/06/2418056/0/en/Spero-Therapeutics-Tebipenem-Pivoxil-Hydrobromide-Phase-3-Data-Published-in-The-New-England-Journal-of-Medicine.html

    GLOBENEWSWIRE
    06 Apr 2022
    Share Share
    Spero Awarded up to $54 M by BARDA and DTRA to Support SPR994 Development
    Spero Awarded up to $54 M by BARDA and DTRA to Support SPR994 Development

    16 Jul 2018

    // PRESS RELEASE

    https://investors.sperotherapeutics.com/news-releases/news-release-details/spero-awarded-54-million-barda-and-dtra-support-spr994

    PRESS RELEASE
    16 Jul 2018
    Share Share
    Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994
    Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994

    09 Jul 2018

    // PRESS RELEASE

    https://investors.sperotherapeutics.com/news-releases/news-release-details/spero-announces-positive-interim-phase-1-sadmad-results-spr994

    PRESS RELEASE
    09 Jul 2018
    Share Share
    Successful USFDA inspection of Asymchem manufacturing facility
    Successful USFDA inspection of Asymchem manufacturing facility

    02 Jun 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/successful-usfda-inspection-of-asymchem-fuxin-1-carbapenem-manufacturing-facility-300658472.html

    PR NEWSWIRE
    02 Jun 2018
    Share Share